Truscreen Test Outperforms Pap Smear in Saudi Arabia Study

Monday 5th August 2024

TruScreen Cervical Cancer Screening Test Outperforms traditional Pap Smear in Saudi Arabia Study

Highlights

• 507 women tested from 2021-2022, results published in July 2024

• High Sensitivity and Specificity: TruScreen demonstrated a sensitivity of 83.3% and a specificity of 95% for detecting cervical lesions (neoplasms), compared to 66.7% and 98.2% for Pap smear, respectively1.

• Real-Time Results: The TruScreen device provides immediate screening results, eliminating the need for laboratory equipment and pathology staff.

• Practical and Reliable: The study confirmed that TruScreen is a practical and reliable screening tool, suitable for use in various healthcare settings.

TruScreen Group Limited (NZX/ASX:TRU) is pleased to announce the preliminary publication, on 25 July 2024, of a study titled “Beyond Tradition: Investigating TruScreen’s Performance Versus Pap Smear in Cervical Cancer Detection” on Research Square1 Link. The preliminary publication is subject to peer review.

Sensitivity Truscreen 83.3% Pap Smear 66.7%

Specificity Truscreen 95% Pap Smear 98.2%

The authors concluded that TruScreen “represents a reliable, practical screening tool for cervical neoplasms” and that their results “provide an evidence-based approach for policymakers when selecting the optimal cervical cancer screening strategy in countries without an established national screening program.”

This study reinforces TruScreen’s commitment to providing innovative and accessible healthcare solutions. The positive results validate TruScreen’s technology and opens new opportunities in the global healthcare market.

Truscreen Cervical Cancer Screening Test Outperforms Traditional Pap Smear in Saudi Arabia Study

Comments from our readers

No comments yet